The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,318.00
Bid: 12,288.00
Ask: 12,292.00
Change: -52.00 (-0.42%)
Spread: 4.00 (0.033%)
Open: 12,326.00
High: 12,428.00
Low: 12,260.00
Prev. Close: 12,318.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

21 May 2014 11:22

RNS Number : 6875H
Bank of America Merrill Lynch
21 May 2014
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the "Code")

 

1.

KEY INFORMATION

(a)

Name of exempt principal trader:

Bank of America Merrill Lynch

(b)

Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

AstraZeneca PLC

(c)

Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc

(d)

Date dealing undertaken:

20/05/2014

(e)

Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2.

DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Class of relevant security

Purchases/sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Common - ISIN GB0009895292

Purchase

101

52.064 EUR

52.064 EUR

Common - ISIN GB0009895292

Purchase

1,630,504

43.085 GBP

41.87 GBP

Common - ISIN GB0009895292

Purchase

1,199,645

478.7 SEK

467.1 SEK

Common - ISIN GB0009895292

Sale

1,621,664

43 GBP

41.9 GBP

Common - ISIN GB0009895292

Sale

1,201,805

477.3 SEK

470.9 SEK

 

(b)

Derivatives transactions (other than options)

Class of relevant security

Product descriptione.g. CFD

Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Common - ISIN GB0009895292

Swaps

Short

104

42.339 GBP

Common - ISIN GB0009895292

Swaps

Short

30,516

42.601 GBP

Common - ISIN GB0009895292

Swaps

Short

4,161

42.601 GBP

Common - ISIN GB0009895292

Swaps

Short

18,531

42.248 GBP

Common - ISIN GB0009895292

Swaps

Long

250,000

42.836 GBP

Common - ISIN GB0009895292

Swaps

Long

200,000

42.86 GBP

Common - ISIN GB0009895292

Swaps

Short

200,000

42.248 GBP

Common - ISIN GB0009895292

Swaps

Short

250,000

42.248 GBP

Common - ISIN GB0009895292

Swaps

Long

85,730

42.896 GBP

Common - ISIN GB0009895292

Swaps

Short

339,723

42.248 GBP

Common - ISIN GB0009895292

Swaps

Long

246,567

42.895 GBP

Common - ISIN GB0009895292

Swaps

Long

1,697

42.224 GBP

Common - ISIN GB0009895292

Swaps

Short

1,697

42.381 GBP

Common - ISIN GB0009895292

Swaps

Short

25,000

42.696 GBP

Common - ISIN GB0009895292

Swaps

Long

136

42.224 GBP

Common - ISIN GB0009895292

Swaps

Short

136

42.381 GBP

Common - ISIN GB0009895292

Swaps

Long

4,015

42.224 GBP

Common - ISIN GB0009895292

Swaps

Short

4,015

42.381 GBP

Common - ISIN GB0009895292

Swaps

Long

300

42.799 GBP

Common - ISIN GB0009895292

Swaps

Short

600

42.156 GBP

Common - ISIN GB0009895292

Swaps

Long

300

42.709 GBP

Common - ISIN GB0009895292

Swaps

Long

13,630

42.224 GBP

Common - ISIN GB0009895292

Swaps

Short

13,630

42.381 GBP

Common - ISIN GB0009895292

Swaps

Short

693

43.085 GBP

Common - ISIN GB0009895292

Swaps

Short

1,565

43.085 GBP

Common - ISIN GB0009895292

Swaps

Short

360

43.085 GBP

Common - ISIN GB0009895292

Swaps

Short

1,589

43.085 GBP

Common - ISIN GB0009895292

Swaps

Short

588

43.085 GBP

Common - ISIN GB0009895292

Swaps

Short

120

42.34 GBP

Common - ISIN GB0009895292

Swaps

Long

300

42.922 GBP

Common - ISIN GB0009895292

Swaps

Long

1,500

42.922 GBP

Common - ISIN GB0009895292

Swaps

Short

101

52.064 EUR

Common - ISIN GB0009895292

Swaps

Long

875

43.082 GBP

Common - ISIN GB0009895292

Swaps

Short

146

43.091 GBP

Common - ISIN GB0009895292

Swaps

Long

952

43.082 GBP

Common - ISIN GB0009895292

Swaps

Long

1,936

473.072 SEK

Common - ISIN GB0009895292

Swaps

Long

124

473.072 SEK

Common - ISIN GB0009895292

Swaps

Short

30,000

42.133 GBP

Common - ISIN GB0009895292

Swaps

Long

20,000

42.661 GBP

Common - ISIN GB0009895292

Swaps

Long

15,000

42.746 GBP

Common - ISIN GB0009895292

Swaps

Long

15,000

42.746 GBP

Common - ISIN GB0009895292

Swaps

Long

20,000

42.746 GBP

Common - ISIN GB0009895292

Swaps

Short

20,000

42.904 GBP

Common - ISIN GB0009895292

Swaps

Long

100

476.229 SEK

Common - ISIN GB0009895292

Swaps

Long

135,541

42.413 GBP

Common - ISIN GB0009895292

Swaps

Short

135,541

42.403 GBP

Common - ISIN GB0009895292

Swaps

Short

102

42.403 GBP

Common - ISIN GB0009895292

Swaps

Long

70,500

42.677 GBP

Common - ISIN GB0009895292

Swaps

Long

4,500

42.677 GBP

Common - ISIN GB0009895292

Swaps

Short

3,500

42.909 GBP

 

(c)

Options transactions in respect of existing securities

(i)

Writing, selling, purchasing or varying

Class ofrelevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number ofsecurities to which option relates

Exercise priceper unit

Typee.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Class of relevant security

Product descriptione.g. call option

Number of securities

Exercise Price per unit

N/A

N/A

N/A

N/A

 

(d)

Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealinge.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

 

The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional classof relevant security dealt in.

 

3.

OTHER INFORMATION

 

(a)

Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"

None

 

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) The voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

 

Date of disclosure:

21/05/2014

Contact name:

Stacy Otieno

Telephone number:

0207 995 1335

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory InformationService and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.The Panel's Market Surveillance Unit is available for consultation in relation to the Code'sdealing disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the "Code")

 

1.

KEY INFORMATION

(a)

Name of exempt principal trader:

Bank of America Merrill Lynch

(b)

Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

Pfizer Inc

(c)

Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc

(d)

Date dealing undertaken:

20/05/2014

(e)

Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2.

DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Class of relevant security

Purchases/sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Common - ISIN US7170811035

Purchase

153

26.2 CHF

26.2 CHF

Common - ISIN US7170811035

Purchase

222

194.5 SEK

193 SEK

Common - ISIN US7170811035

Sale

153

26.2 CHF

26.2 CHF

Common - ISIN US7170811035

Sale

222

194.5 SEK

193 SEK

 

(b)

Derivatives transactions (other than options)

Class of relevant security

Product descriptione.g. CFD

Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

N/A

N/A

N/A

N/A

N/A

 

(c)

Options transactions in respect of existing securities

(i)

Writing, selling, purchasing or varying

Class ofrelevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number ofsecurities to which option relates

Exercise priceper unit

Typee.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Class of relevant security

Product descriptione.g. call option

Number of securities

Exercise Price per unit

N/A

N/A

N/A

N/A

 

(d)

Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealinge.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

 

The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional classof relevant security dealt in.

 

3.

OTHER INFORMATION

 

(a)

Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"

None

 

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) The voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

 

Date of disclosure:

21/05/2014

Contact name:

Stacy Otieno

Telephone number:

0207 995 1335

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory InformationService and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.The Panel's Market Surveillance Unit is available for consultation in relation to the Code'sdealing disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBGGDUBDDBGSB
Date   Source Headline
9th Aug 20199:28 amRNSAmendment: Tagrisso significantly improves overall
9th Aug 20197:00 amRNSTagrisso significantly improves overall survival
7th Aug 20197:00 amRNSLynparza Phase III PROfound trial in HRR*
5th Aug 20197:00 amRNSForxiga label updated in the EU in type-2 diabetes
1st Aug 20193:00 pmRNSTotal Voting Rights
25th Jul 20197:00 amRNSAZN: H1 2019 Results
15th Jul 20197:00 amRNSUpdate on US regulatory decision for Farxiga
12th Jul 20197:00 amRNSImfinzi granted US Orphan Drug Designation for
1st Jul 20193:00 pmRNSTotal Voting Rights
1st Jul 20197:00 amRNSForxiga receives positive EU CHMP opinion for
1st Jul 20197:00 amRNSFasenra receives positive EU CHMP opinion for self
27th Jun 20197:00 amRNSImfinzi improves overall survival at interim
19th Jun 20197:00 amRNSBreztri Aerosphere (PT010) approved in Japan for
19th Jun 20197:00 amRNSLynparza approved in Japan for 1st-line
19th Jun 20197:00 amRNSBevespi Aerosphere approved by the Japanese
18th Jun 20197:00 amRNSLynparza approved in the EU for 1st-line
17th Jun 20197:00 amRNSCalquence significantly prolonged the time patient
12th Jun 20194:45 pmRNSPublication of a Prospectus
6th Jun 20197:00 amRNSCalquence Phase III ELEVATE-TN trial met primary
5th Jun 201912:36 pmEQSHardman & Co Research: AstraZeneca: Where has all the cash gone?
3rd Jun 20193:00 pmRNSBlock listing Interim Review
3rd Jun 20193:00 pmRNSTotal Voting Rights
3rd Jun 20197:00 amRNSLynparza nearly doubled time patients lived with
10th May 20197:00 amRNSPooled analyses of the roxadustat global Phase III
8th May 20192:00 pmRNSDirector/PDMR Shareholding
8th May 201911:00 amRNSDirector Declaration
8th May 20197:00 amRNSTrastuzumab deruxtecan demonstrated clinically
7th May 20197:00 amRNSCalquence PhIII ASCEND trial met primary endpoint
3rd May 20197:00 amRNSQternmet XR approved in the US for type-2 diabetes
1st May 20193:00 pmRNSTotal Voting Rights
1st May 201912:00 pmRNSDirector/PDMR Shareholding
29th Apr 20197:00 amRNSLynparza receives positive EU CHMP opinion for 1st
26th Apr 20195:45 pmRNSResult of AGM
26th Apr 20197:00 amRNSAZN: Q1 2019 Results
10th Apr 20197:00 amRNSLynparza approved in EU for the treatment of germl
9th Apr 20194:10 pmEQSHardman & Co Research: Global Pharmaceuticals: 2018 industry sales
4th Apr 20191:30 pmRNSHolding(s) in Company
3rd Apr 201910:00 amRNSDirector/PDMR Shareholding
2nd Apr 20193:00 pmRNSTotal Voting Rights
1st Apr 20196:00 pmRNSAstrazeneca
1st Apr 20193:00 pmRNSTotal Voting Rights
1st Apr 20197:00 amRNSSelumetinib gets Breakthrough Therapy Designation
29th Mar 20195:15 pmRNSResults of Placing
29th Mar 20197:00 amRNSProposed placing of new ordinary shares
29th Mar 20197:00 amRNSAZ and Daiichi Sankyo enter collaboration in novel
27th Mar 20197:00 amRNSForxiga approved in Japan for type-1 diabetes
25th Mar 20197:00 amRNSForxiga approved in Europe for type-1 diabetes
18th Mar 20197:00 amRNSUS FDA grants saracatinib ODD for IPF
14th Mar 201912:00 pmRNSNotice of AGM
12th Mar 201912:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.